1. Introduction {#sec1}
===============

Crigler-Najjar syndrome (CNS) (MIM nos. 218800, 606785) type I and type II are inherited as autosomal recessive conditions that are caused by mutations in the *UGT1A1*gene (*UGT1A1*; MIM no. 191740) \[[@B1]--[@B6]\]. Type I is characterized by almost complete absence of UGT1A1 enzyme activity, in which the affected individuals are refractory to phenobarbital treatment, while type II is a less severe form of deficiency \[[@B6], [@B7]\]. Patients with CNS are at permanent risk of developing severe neurologic complications such as hearing problems, mental retardation, and choreoathetosis due to severe unconjugated hyperbilirubinemia \[[@B8]\]. The high performance liquid chromatography (HPLC) analysis of liver enzyme assay is the conclusive diagnosis of this syndrome \[[@B9]\]. The *UGT1A1*gene comprises five consecutive exons located at the 3′end of the *UGT1A*locus on chromosome 2q37.

Mutations in the *UGT1A1*gene occur in any of the five exons, which either completely (CNS-I) or partially (CNS-II) inactivate this enzyme and result in a truncated protein. Here, we present the analysis of *UGT1A1*gene in 12 unrelated individuals from three different families.

2. Subjects and Methods {#sec2}
=======================

2.1. Cases History {#sec2.1}
------------------

*Family A.* The patient was a 9-month-old boy who has had jaundice 72 h after birth continuously, with high total and direct bilirubin values ([Table 2](#tab2){ref-type="table"}). His first blood examination revealed a normal hemoglobin level (12.5 g/dL), RBC (4.89 M/*μ*L), MCV (74.8 fL), MCH (25.6 pg), MCHC (34.2 g/dL), and platelet count (299 k/*μ*L). Both parents (22-year-old father and 21-year-old mother) were educated with a history of mild jaundice, consanguinity, and mental disorders in their relatives. During a seven-day course of phototherapy treatment without phenobarbital, the serum bilirubin has dropped to 23 mg/dL. There was no evidence of neurotoxicity. He was transferred to our department for further diagnosis.

*Family B.* A pregnant woman with a fetus was referred to our department at gestational age of 18 weeks for amino synthesis. Both parents (28-year-old father and 26-year-old mother) were educated with no history of consanguinity and mental disorders in their relatives. Their other child was an 11-year-old girl with jaundice. Her first blood examination revealed hemoglobin (14.2 g/dL), RBC (5.60 M/*μ*L), MCV (82.0 fL), MCH (25.6 pg), MCHC (31.2 g/dL), and platelet (217 k/*μ*L). Her family history revealed that her parents had mild jaundice ([Table 2](#tab2){ref-type="table"}). Her birth weight was 3500 g following normal pregnancy and uneventful cesarean section. This girl developed clinical jaundice by 4 days of age with total and direct bilirubin of 26 mg/dL and 1.5 mg/dL, respectively. Her hyperbilirubinemia responded to a 12-day course of phototherapy without phenobarbital, and total bilirubin was reduced to 13 mg/dL. She was discharged under phenobarbital therapy, but her hyperbilirubinemia rebounded quickly, and she was admitted again with a total bilirubin of 29 mg/dL and was transferred to our department for further diagnosis.

*Family C.* A consanguine couple (29-year-old male and 26-year-old female) was referred to our department for premarital genetic counseling and screening of CNS. The patient was a 29-year-old male who has had jaundice, with a total bilirubin of 8.4 mg/dL, direct bilirubin of 1.8 mg/dL, and blood examination results of hemoglobin (15.2 g/dL), RBC (4.67 M/*μ*L), MCV (79.1 fL), MCH (24.2 pg), MCHC (32.8 g/dL), and platelet count (287 k/*μ*L). The man had a family history of CNS. His parents (52-year-old father and 49-year-old mother) were not educated with a history of slight elevation in bilirubin ([Table 2](#tab2){ref-type="table"}) and consanguinity and no history of mental disorders in their relatives. Their other child was an 11-year-old boy with jaundice, with a total and direct bilirubin of 26 mg/dL and 0.56 mg/dL, respectively. The woman was normal with no history of CNS in her family and relatives.

2.2. Molecular Genetic Analysis {#sec2.2}
-------------------------------

### 2.2.1. DNA Extraction and Nucleotide-Sequence Analysis {#sec2.2.1}

Following the approval of the local ethics committee of Ahvaz Jundishapur University of Medical Sciences (AJUMS) and taking a written informed consent from parents, peripheral blood samples were obtained. Genomic DNA was isolated from peripheral blood of the patients, their parents, and several normal individuals using a routine phenol-chloroform method. All five coding exons and the flanking intronic regions of the bilirubin-UGT were amplified by polymerase chain reaction (PCR), according to Bosma et al., method \[[@B10]--[@B12]\]. Then, all PCR products were sequenced using designed primers (Primer 3.0 web based software, University of Massachusetts Medical School, USA) ([Table 1](#tab1){ref-type="table"}).

The reaction mixture (30 *μ*L) contains 2 *μ*L of genomic DNA, 1 *μ*L of each upstream and downstream primer (diluted to 10 *μ*mol/L), 11 *μ*L of ddH~2~O, 15 *μ*L of 2 × Taq PCR Master Mix (Qiagen Inc.) were used, as described by Wang et al., recently. In brief, PCR was implemented by denaturation at 95°C for 3 min, followed by 40 thermal cycles composed of 94°C for 30 sec, 55°C for 30 sec, and 72°C for 45 sec for each. Furthermore, the amplified products were isolated by electrophoresis on a 1% agarose gel and then purified using the QIAamp purification kit (Qiagen Inc.), and the nucleotide sequence was determined by direct sequencing using an ABI 310 automatic sequencer according to the manufacturer\'s instructions (Applied Biosystem, Foster City, CA, USA).

3. Results {#sec3}
==========

From family A, a 9-month-old boy with clinical CNS was homozygous for a 2-bp deletion mutation causing a change of the coding exons with a frameshift. The deletion of one adenosine (A) and one glutamine (G) between nucleotides 238 and 240 in exon 1 ([Figure 1](#fig1){ref-type="fig"}) modified the nucleotide of codons 238, 239, and 240 ([Table 2](#tab2){ref-type="table"}). Sequencing showed the homozygous mutation, which had not been reported so far. The evaluation of parents revealed the heterozygous pattern of the same mutation in both ([Figure 1](#fig1){ref-type="fig"} and [Table 2](#tab2){ref-type="table"}). In family B, there were two individuals (B and C), an 11-year-old girl and 18-week old fetus. Patient B, a girl with clinical CNS, and patient C, a fetus, were homozygous for the same deletion as patient A ([Figure 2](#fig2){ref-type="fig"}). Both parents were also heterozygous for the same mutation ([Figure 1](#fig1){ref-type="fig"} and [Table 2](#tab2){ref-type="table"}).

In family C, there were two boys and their parents with clinical CNS. From these four subjects, three were heterozygous and one was homozygous for substitution mutation. Polymerase chain reaction and sequence analysis of the *UGT1A1*gene revealed a T\>A mutation at nucleotide 479 in exon 1 (Val160Glu) that has been reported previously ([Table 2](#tab2){ref-type="table"}) \[[@B2]\].

4. Discussion {#sec4}
=============

Mutations in the *UGT1A1* gene were previously shown to cause CNS. Here we describe a unique etiology of CNS in three affected families, which was analyzed using direct sequencing of whole coding sequences and splice sites of the *UGT1A1* gene. Overall seven heterozygous and four homozygous cases were observed. The deletion mutation in exon 1 may alter the structure of a protein called UDPGT due to the frameshift. The enzymatic activity of the resulting protein may reduce because it has amino acids that are different in addition to the premature translation at the codon of interest.

CNS is a rare entity with only few hundred cases reported since the first report in 1952 \[[@B13]\]. The incidence of CNS is estimated in a range of 0.6--1.0 per million live births \[[@B14]\]. Although the clinical characteristics of our patients were consistent with prior reported cases, the observed mutation was novel and different. Bilirubin encephalopathy due to CNS may occur without well-timed treatment \[[@B15]\].

Careful phenotypic analysis of patients who have disorders caused by UDPGT can be informative for identification of parent-of-origin differences in gene expression. Consistent with this, the mother and the father, who were heterozygous for the c.238_240del, had normal or slightly elevated serum bilirubin. It can be deduced, therefore, that in the case, homozygous for the novel deletion at the exon 1, was required for the expression of the jaundiced phenotype. Although over 65 different genetic mutations in the coding region of *UGT1A1*gene have been described to cause CNS, \[[@B16], [@B17]\] the novel deletion reported here was found to inactivate the enzyme.

The characterization of a genetic defect which is present in the large majority of subjects with CNS makes a genetic test for this disorder feasible, if not practical. Moreover, knowing the molecular genetics of CN has clinical consequences that are not limited to the field of familial unconjugated hyperbilirubinemias. In all these instances, direct recognition of the role of CNS may help in the diagnostic and therapeutic management of the patient, by ruling out more harmful causes of hyperbilirubinemia.

In conclusion, we report a novel deletion within exon 1 of *UGT1A1*gene, causing the jaundiced phenotype, thereby inactivating the enzyme. Though *UGT1A1* gene is expressed specifically in the liver, we made an attempt to define the diagnosis and the molecular mechanism of *UGT1A1* deficiency by a noninvasive molecular approach, not demanding a liver biopsy. This method not only is valuable in starting the clinical diagnosis and given that genetic counseling, but also could help the novel gene therapy approaches that involve the knowledge of the specific genetic lesion in a patient.
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###### 

*UGT1A1* gene primers used in PCR and sequencing.

  Region         Primer                   Primer sequence (5′→3′)
  -------------- ------------------------ -------------------------
  Pro            GCDH_pro_1F              GCTACTTGGAGGCTGAGGTG
  GCDH_pro_1R    TGAGGCTTTTCATTGGTTCC     
  Pro            GCDH_pro_2F              AACTGACCAACCAGGAGTGG
  GCDH_pro_2R    CTCTCAGGGCCATGCTCTCT     
  Exon 1         GCDH9_ex1F               GATTTCCACAGGCAAGGCTA
  GCDH_ex1R      CTCCTTCCCTCCACACTCC      
  Exon 2         GCDH_ex2F                GGAACCAATGAAAAGCCTCA
  GCDH_ex2R      GCGACCAGAGGTCCTTACAC     
  Exon 3         GCDH_ex3F                TCGCTCTGAGAGAGCATGG
  GCDH_ex3R      CTGCCTTAGTGCCTCTGACC     
  Exon 4         GCDH_ex4F                CAGGGTCAGAGGCACTAAGG
  GCDH_ex4R      GAAAAACTGCAAAGGGACCA     
  Exon 5         GCDH_ex5F                AGATCCTCATCAGGGACACCT
  GCDH_ex5R      CCAGCTACTAGAGGGGTGGAG    
  Exon 6         GCDH_ex6F                GCCACAATTTCCCAGTCTGT
  GCDH_ex6R      CAGAATAGGCTCAGGGGACA     
  Exon 7         GCDH_ex7F                CATATTGGTCAGGCTGGATTTT
  GCDH_ex7R      CACTACAAACAGATCGGCCATA   
  Exon 8         GCDH_ex8F                TGGGACCAAGACCTGGTAAG
  GCDH_ex8R      CCGGCTGAGTAAGAATCACC     
  Exon 9         GCDH_ex9F                TTCCCTGCTTCAGAGTTGGT
  GCDH_ex9R      AGGACGTCACTGGTCATTCC     
  Exon 10        GCDH_ex10F               CAGTGACGTCCTTCTGAGCA
  GCDH_ex10R     AGGACAAGAGGGACAGCAGA     
  Exon 11        GCDH_ex11F               GGACCTGAACCTTCTGCTGT
  GCDH_ex11R     CTCCAGATGAGGGACAGAGG     
  Exon 12        GCDH_ex12_1F             TGGCCTCACAGTCTTCTCCT
  GCDH_ex12_1R   CTCCCTCACTCTGCTCCAAC     
  Exon 12        GCDH_ex12_2F             GGATGGAGTGGGAAGTGAGA
  GCDH_ex12_2R   CCAGACCACTCTAGGGGAAA     

###### 

Mutations identified in patients with Crigler-Najjar syndrome (CNS).

  Patients   Reported consanguinity   Bilirubin (mg/dL)   Age/sex (F: female; M: male)   Mutation          Polymorphisms                Reference   
  ---------- ------------------------ ------------------- ------------------------------ ----------------- ---------------------------- ----------- ------------------------------
  Family A                                                                                                                                          
  CNS-1      Yes                      31.2                1.79                           9-month-old/M     c.238_240del/c.238_240del    Del(AG)     Novel
  CNS-2      Yes                      1.53                0.97                           22-year-old/M     c.238_240del/N               Del(AG)     Novel
  CNS-3      Yes                      2.1                 1.22                           21-year-old/F     c.238_240del/N               Del(AG)     Novel
                                                                                                                                                    
  Family B                                                                                                                                          
  CNS-4      No                       ---                 ---                            18 weeks GA/---   c.238_240del/ c.238_240del   Del(AG)     Novel
  CNS-5      No                       3.6                 1.78                           28-year-old/M     c.238_240del/N               Del(AG)     Novel
  CNS-6      No                       1.69                1.01                           26-year-old/F     c.238_240del/N               Del(AG)     Novel
  CNS-7      No                       26                  1.5                            11-year-old/F     c.238_240del/c.238_240del    Del(AG)     Novel
                                                                                                                                                    
  Family C                                                                                                                                          
  CNS-8      Yes                      26                  0.56                           11-year-old/M     c.479T\>A/c.479T\>A          T\>A        Huang et al., 2006 \[[@B2]\]
  CNS-9      Yes                      1.48                0.99                           49-year-old/F     c.479T\>A/N                  T\>A        Huang et al., 2006 \[[@B2]\]
  CNS-10     Yes                      2.61                1.13                           52-year-old/M     c.479T\>A/N                  T\>A        Huang et al., 2006 \[[@B2]\]
  CNS-11     Yes                      8.4                 1.8                            29-year-old/M     c.479T\>A/N                  T\>A        Huang et al., 2006 \[[@B2]\]
  CNS-12     Yes                      0.8                 0.3                            28-year-old/F     N/N                          T\>A        Huang et al., 2006 \[[@B2]\]
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